Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Follicular 8Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 5Lymphoma, B-Cell, Marginal Zone 5Hodgkin Disease 4Waldenstrom Macroglobulinemia 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Stomach Neoplasms 1Rectal Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Disease Progression 1Colorectal Neoplasms 1

Interventions

fludarabine phosphate 29Peripheral Blood Stem Cell Transplantation 26Cyclophosphamide 25ruxolitinib 22Busulfan 21Tacrolimus 16Whole-Body Irradiation 15Mycophenolic Acid 14Methotrexate 13Cyclosporine 12Antilymphocyte Serum 11Hydroxyurea 10Aspirin 9fludarabine 8Filgrastim 8Melphalan 7Etoposide 7Decitabine 7peginterferon alfa-2a 6Imatinib Mesylate 6Cytarabine 611-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6givinostat hydrochloride 5givinostat 5Radiotherapy 5Prednisone 5Carboplatin 5Biopsy 5Topotecan 4Thiotepa 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Polycythemia Vera × umbralisib × Clear all
NCT02493530 2026-05-19

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Vanderbilt-Ingram Cancer Center

Phase 1 Completed
60 enrolled
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡